← Search & browse all drugs

thymalfasin

L03AX25

Forms & Strengths

Injectable solution: 1.6 mg per vial

Adult Dosing

Hepatitis B: 1.6 mg subcutaneously twice weekly for 6 months
Hepatitis C: 1.6 mg subcutaneously twice weekly for 6-12 months, often combined with antivirals

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established

Indications

Treatment of chronic hepatitis B
Treatment of chronic hepatitis C (off-label or regional approvals)
Immunomodulator for enhancement of immune response in various malignancies and immunodeficiency states (regional variations)

Mechanism of Action

Synthetic thymic hormone analog that enhances immune function
Stimulates T-cell maturation, increases T-cell and NK-cell counts, and enhances lymphokine-activated killer cell activity

Contraindications

Hypersensitivity to thymalfasin or thymic extracts
Patients receiving immunosuppressive therapy (e.g., post-organ transplant)
Severe immunodeficiency where immune stimulation is contraindicated

Adverse Reactions

Injection site pain, erythema, or irritation
Fever, malaise, and flu-like symptoms
Transient elevations in transaminases (flare reactions in hepatitis treatment)
Headache, fatigue, and nausea

Drug Interactions

Immunosuppressants (e.g., cyclosporine, corticosteroids): may antagonize the therapeutic immunomodulatory effects of thymalfasin
Interferons and antiviral agents: may have additive or synergistic efficacy in viral hepatitis

Curated Content: Needs Vetting Before Put to Clinical Use